| 11ª Semana de Integração Acadêmica da UFRJ |
|
2022 |
| Associação da produção das citocinas TNF-alfa e IL-10, com o processo de cicatrização de incisões operatórias na parede abdominal em ratos Wistar (Rattus norvegicus). |
|
2018 |
| Identification of conserved linear epitope as target of protective antibodies in visceral leishmaniasis |
|
2018 |
| Challenges and solutions to tailor an anti-leishmania vaccine to the needs of specific regions: a nanomedical approach |
|
2017 |
| Immunotherapy against visceral leishmaniasis caused by L. (L.) chagasi with the recombinant chimera containing the N- and C- domains of Leishmania (L.) donovani nucleoside hidrolase |
|
2016 |
| F2 DOMAIN OF LEISHMANIA NUCLEOSIDE HYDROLASE INDUCES RESISTENCE-ASSOCIATED T-CELL RESPONSES IN HUMAN VISCERAL LEISHMANIASIS |
|
2016 |
| IMMUNOTHERAPY AGAINST VISCERAL LEISHMANIASIS CAUSED BY L.(L) CHAGASI WITH THE RECOMBINANT CHIMERA CONTAINING THE N- AND C- DOMAINS OF LEISHMANIA (L.) DONOVANI NUCLEOSIDE HYDROLASE |
|
2016 |
| The F1 domain is the antibody target of L. (L.) donovani Nucleoside hydrolase NH36 in subclinical DTH+ and cured human patients of visceral leishmaniasis from Aracaju (SE). |
|
2014 |
| Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains. |
|
2014 |
| . Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection |
|
2014 |
| . Multifuncional TH1 cell response against nucleoside hydrolase (NH) of Leishmania donovani (NH36) and its epitopes in human visceral leishmaniasis. |
|
2014 |
| Antigenicity of F1, F2, F3 and NH36 in exposed individuals to L infantum. in Madrid (Spain). |
|
2014 |
| Cross-protective effect of vaccination with the recombinant chimera containing the N- and C- domains of Nucleoside hydrolase from Leishmania (L.) donovani terminals on prophylaxis of murine cutaneous leishmaniasis by Leishmania (L.) amazonensis. |
|
2014 |
| Quality of type 1 immune response induced by Leishmania (L.) donovani nucleoside hydrolase (NH36) peptides in peripheral blood mononuclear cells obtained from cutaneous leishmaniasis patients |
|
2014 |
| . Immucillins are potente compounds that impair Leishmania infantum and Leishmania amazonensis multiplication in vitro. |
|
2014 |
| Human influenza viruses inactivated by hydrostatic pressure: investigating a candidate for a universal vaccine |
|
2014 |
| A recombinant chimera containing the C- and N-terminal moieties of the Nucleoside hydrolase (NH36) of Leishmania (L.) donovani prophylaxis of mice against Leishmania (L.) infantum infection. |
|
2014 |
| Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+-epitopes of Leishmania donovani Nucleoside Hydrolase terminal. |
|
2013 |
| Vaccination with Nucleoside Hydrolase (NH36) of L. (L.) donovani or its C-terminal portion (F3) in formulation with saponin prevent the defective migration of dendritic cells in murine experimental visceral leishmaniasis. |
|
2013 |
| Vaccination with nucleoside Hydrolase (NH36) of L.(L.) donovani or its C-terminal portion (F3) in formulation with saponin prevent the defective migration of dendritic cells in murine experimental visceral leishmaniasis |
|
2013 |
| Immunization with the C-Terminal Domain Peptides of Leishmania (L.) donovani Nucleoside Hydrolase (NH36) aiming the identification of main epitopes |
|
2012 |
| Immunotherapy against Leishmania (L.) amazonensis infection with Nucleoside Hidrolase (NH36) peptides of Leishmania (L.) amazonensis |
|
2012 |
| Immunotherapy against Visceral Leishmaniasis with Nucleoside Hidrolase peptides of Leishmania (L.) donovani |
|
2012 |
| Cloning of the C-terminal domain peptides of Leishmania donovani nucleoside hydrolase (NH¨36) aiming the identification of antibody epitopes. |
|
2011 |
| Increase of the adjuvant capability of Chiococca alba saponin by the increase of one sugar residue in the C-28 triterpene attached sugar chain. Effect on protection against visceral leishmaniasis. |
|
2011 |
| Immunotherapy with the Leishmune's nucleoside hydrolase DNA vaccine reduces infection and increases survival in a canine |
|
2011 |
| Mice vaccination with H3N8 inactivated by high hydrostatic pressure protect against experimental avian flu. |
|
2011 |
| Partial contribution of the B2 receptor of the kinin inflamation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of Nucleoside hydrolase vaccine. |
|
2011 |
| Vaccination with the Leishmune®´s Nucleoside Hydrolase Maps the C-Terminal Domain as the Target of the Protective Immune Response |
|
2010 |
| Comparison the Prophylactic Potential of the Nucleoside Hydrolase Genetic Vaccine on Visceral Leishmaniasis Administered in Mice through the Intramuscular or the Intranasal Route |
|
2010 |
| Comparison of Adjuvant Potential of a QS21-Containing Saponin and the CA3 and CA4 Saponins from Chiococca alba (L.) Hitch in Murine Vaccination against Visceral Leishmaniasis with the FML Antigen |
|
2010 |
| Inactivation by Hydrostatic Pressure Preserves the Hemagglutinin and Neuraminidase Activities of the Avian Influenza Virus H3N8 |
|
2010 |
| VACCINATION WITH THE LEISHMUNE®´S NUCLEOSIDE HYDROLASE MAPS THE C-TERMINAL DOMAIN AS THE TARGET OF THE PROTECTIVE IMMUNE RESPONSE |
|
2010 |
| COMPARISON THE PROPHYLACTIC POTENTIAL OF THE NUCLEOSIDE HYDROLASE GENETIC VACCINE ON VISCERAL LEISHMANIASIS ADMINISTERED IN MICE THROUGH THE INTRAMUSCULAR OR THE INTRANASAL ROUTE |
|
2010 |
| Identification of the Leishmania donovani Nucleoside Hydrolase (NH36)-Peptide Sequences Containing Epitopes Involved in Protective Immune Response against Murine Visceral Leishmaniasis |
|
2009 |
| Development of a Second-Generation Vaccine against Dengue |
|
2009 |
| Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. |
|
2008 |
| Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL) |
|
2008 |
| Identification of potential MHC class I and II epitopes and cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. |
|
2007 |
| Cross-protective efficacy of the prophylactic VR1012-NH36 Leishmania donovani-DNA vaccine against cutaneous murine leishmaniasis by Leishmania amazonensis |
|
2007 |
| Kinins generated upon vaccination with the QS21 saponin-containing Leishmune® vaccine are partially responsible for induction of protective immunity against visceral leishmaniasis |
|
2007 |
| Structure-function studies of the novel CP05 saponin of Calliandra pulcherrima Benth adjuvant: asseeement of monoterpene, glycidic fractions and triterpene in adjuvant function |
|
2006 |
| Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine agianst visceral leishmaniasis. |
|
2006 |
| Assentement of the monoterpene, glycidic and triterpene-moieties contribuition of the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth. |
|
2006 |
| The FML-vaccine Leishmune R against canine visceral leishmaniasis: a transmission blocking vaccine |
|
2006 |
| Comparative Adjuvant potential of the QS21 and CP05 purified saponins in the FML vaccine against murine visceral leishmaniasis |
|
2005 |
